Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

First Infection with Absidia Corymbifera in a CLL Patient - Ibrutinib As Risk Factor?

Matthes Marquardt, MD, Maren Thiel, MD, Silke Kerl, MD, Michael Wöhlke, MD, Katrin Gröpler, MD, Dietrich Gläser, MD, Andreas Guenther, MD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-135961

Published: 2020

Journal Articles

Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)

Blood (2018) 132 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2018-99-113340

Published: 2018

Journal Articles

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Anna Sophie Hartjen, Andreas Krumbholz, MD, Florian Thieme, PhD, Natalie Schub, MD, Andreas Humpe, MD, Michaela Kotrova, Monika Brüggemann, MD, Martin Gramatzki, MD, Andreas Guenther, MD

Blood (2017) 130 (Supplement 1): 5490.

https://doi.org/10.1182/blood.V130.Suppl_1.5490.5490

Published: 2017

Journal Articles

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Blood (2016) 128 (22): 5692.

https://doi.org/10.1182/blood.V128.22.5692.5692

Published: 2016

Journal Articles

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2016) 128 (22): 4471.

https://doi.org/10.1182/blood.V128.22.4471.4471

Published: 2016

Journal Articles

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 3026.

https://doi.org/10.1182/blood.V126.23.3026.3026

Published: 2015

Journal Articles

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Blood (2015) 126 (23): 4230.

https://doi.org/10.1182/blood.V126.23.4230.4230

Published: 2015

Journal Articles

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Blood (2014) 124 (21): 4742.

https://doi.org/10.1182/blood.V124.21.4742.4742

Published: 2014

Journal Articles

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2014) 124 (21): 2120.

https://doi.org/10.1182/blood.V124.21.2120.2120

Published: 2014

Journal Articles

MSH-TP15 Identified By Phage Display Technology Detects a Target Structure For Antibody-Mediated Killing In Multiple Myeloma

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Pia Glorius, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2013) 122 (21): 4442.

https://doi.org/10.1182/blood.V122.21.4442.4442

Published: 2013

Journal Articles

Selective Inhibition Of The PI3K-Alpha Isoform Blocks Myeloma Cell Growth and Survival

Andreas Guenther, MD, Renate Burger, PhD, Wolfram Klapper, Matthias Staudinger, PhD, Martin Gramatzki, MD

Blood (2013) 122 (21): 5364.

https://doi.org/10.1182/blood.V122.21.5364.5364

Published: 2013

Journal Articles

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Jesús F. San-Miguel, MD, PhD, Orhan Sezer, MD, PhD, David Siegel, Andreas Guenther, MD, Maria-Victoria Mateos, MD, PhD, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Michele Cavo, MD, Joan Blade, MD, Mario Boccadoro, MD, Bourras R. Bengoudifa, Martin Klebsattel, PhD, Priscille M. Bourquelot, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3852.

https://doi.org/10.1182/blood.V114.22.3852.3852

Published: 2009

Journal Articles

The Green Tea Polyphenol Epigallocatechin Gallate (EGCG) Antagonizes the Inhibitory Effect of Bortezomib on Myeloma Cells.

Renate Burger, PhD, Hanna Czekalla, Tanja Ahrens, Kathrin Richter, Andreas Guenther, MD, Martin Gramatzki, MD

Blood (2007) 110 (11): 4794.

https://doi.org/10.1182/blood.V110.11.4794.4794

Published: 2007

Journal Articles

Green Tea Polyphenol (−)-Epigallocatechin Gallate Inhibits IL-6 Mediated Signalling Pathways in Human Myeloma Cells.

Renate Burger, PhD, Hanna Czekalla, Kathrin Richter, Tanja Ahrens, Andreas Guenther, MD, Martin Gramatzki, MD

Blood (2006) 108 (11): 5049.

https://doi.org/10.1182/blood.V108.11.5049.5049

Published: 2006

Journal Articles

Zoledronate Exerts Direct Antiproliferative and Apoptotic Effects on Human Myeloma Cells In Vitro and In Vivo .

Andreas Guenther, MD, Sharon Gordon, PhD, Frank Bakker, PhD, Renate Burger, PhD, Markus Tiemann, MD, Jonathan R. Green, MD, Michael Rogers, PhD, Martin Gramatzki, MD

Blood (2005) 106 (11): 3387.

https://doi.org/10.1182/blood.V106.11.3387.3387

Published: 2005

Journal Articles

Synergistic Inhibition of Myeloma Cell Growth by Combinations of Dexamethasone with Other Anti-Myeloma Agents.

Frank Bakker, PhD, Andrea Ott, Kathrin Richter, Tanja Ahrens, Andreas Guenther, MD, Renate Burger, PhD, Martin Gramatzki, MD

Blood (2005) 106 (11): 5105.

https://doi.org/10.1182/blood.V106.11.5105.5105

Published: 2005

Journal Articles

POEMS Syndrome: A Patient with an IgA lambda Plasma Cell Disease. Expression Levels of VEGF and bFGF Correlates with Clinical Course.

Carsten Schrader, MD, Markus Tiemann, MD, Ute Zirrgiebel, Andreas Guenther, MD, Dirk Janssen, MD, Michael Kneba, MD, Martin Gramatzki, MD

Blood (2005) 106 (11): 5516.

https://doi.org/10.1182/blood.V106.11.5516.5516

Published: 2005

Journal Articles

Zoledronic Acid Inhibits Protein Prenylation in Plasmacytoma Tumors In Vivo and Enhances Survival in the INA-6 SCID Mouse Model.

Andreas Guenther, MD, Sharon Gordon, PhD, Frank Bakker, PhD, Renate Burger, PhD, Jonathan R. Green, PhD, Michael Rogers, PhD, Martin Gramatzki, MD

Blood (2004) 104 (11): 3360.

https://doi.org/10.1182/blood.V104.11.3360.3360

Published: 2004

NARROW

First Infection with Absidia Corymbifera in a CLL Patient - Ibrutinib As Risk Factor?

Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

MSH-TP15 Identified By Phage Display Technology Detects a Target Structure For Antibody-Mediated Killing In Multiple Myeloma

Selective Inhibition Of The PI3K-Alpha Isoform Blocks Myeloma Cell Growth and Survival

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

The Green Tea Polyphenol Epigallocatechin Gallate (EGCG) Antagonizes the Inhibitory Effect of Bortezomib on Myeloma Cells.

Green Tea Polyphenol (−)-Epigallocatechin Gallate Inhibits IL-6 Mediated Signalling Pathways in Human Myeloma Cells.

Zoledronate Exerts Direct Antiproliferative and Apoptotic Effects on Human Myeloma Cells In Vitro and In Vivo .

Synergistic Inhibition of Myeloma Cell Growth by Combinations of Dexamethasone with Other Anti-Myeloma Agents.

POEMS Syndrome: A Patient with an IgA lambda Plasma Cell Disease. Expression Levels of VEGF and bFGF Correlates with Clinical Course.

Zoledronic Acid Inhibits Protein Prenylation in Plasmacytoma Tumors In Vivo and Enhances Survival in the INA-6 SCID Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only